RAF1 and chronic myelogenous leukemia, BCR-ABL1 positive: HFA of the ESC Cardio-Oncology Study Group in collaboration with the ICOS had developed a baseline CV risk assessment proformas for seven cardiotoxic cancer therapy classes known to cause a range of CV toxicities.28 Separate proformas are used for these seven drug classes including Anthracycline chemotherapy, HER2 targeted therapies, VEGFIs, MKIs for CML targeting BCR-ABL, MKIs for CML targeting BCR-ABL, Proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs), Combination RAF and MEK inhibitor treatment, Androgen deprivation therapies (ADT), Immune checkpoint inhibitors.